BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bipolar Depression readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Bipolar Depression\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06372964-872@assetmemo.bio
DTSTAMP:20261121T004522Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06372964)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Bipolar Depression.\nStudy: 
 Multicenter Study of Lumateperone for the Treatment of Bipolar Depression 
 in Pediatric Patients\nEstimated primary completion: 31 October 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06372964
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
